A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2006
12/28/2006	US20060293239 Treatment and Diagnosis of Insulin-Resistant States
12/28/2006	US20060293238 Inactivation resistant factor VIII
12/28/2006	US20060293237 an octapeptide that selectively activates the Receptors for Activated C-Kinase (RACK) in cardiomyocytes and is linked to a tat-peptide or polyarginine peptide; peptide can be administered before, during or after the ischemic or hypoxic events; antiischemic, antihypoxic agents
12/28/2006	US20060293236 Injectable Osteogenic Formula and Method of Using Same
12/28/2006	US20060293235 HGF beta chain variants
12/28/2006	US20060293234 Interaction between MUC1 and beta -catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1, whereby interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis
12/28/2006	US20060293233 Compositions and methods for modulating body weight and treating obesity-related disorders
12/28/2006	US20060293232 Hybrid polypeptides with selectable properties
12/28/2006	US20060293231 Method for enhancing bone formation
12/28/2006	US20060293230 Expression and secretion of icIL-1 receptor antagonist type II
12/28/2006	US20060293229 Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
12/28/2006	US20060293228 Therapeutic compositions and methods using transforming growth factor-beta mimics
12/28/2006	US20060293227 Cosmetic compositions and methods using transforming growth factor-beta mimics
12/28/2006	US20060293226 Medicament and use thereof for tumor therapy
12/28/2006	US20060293225 Gmg-2 polynucleotides and polypeptides and uses thereof
12/28/2006	US20060293224 Conformationally stabilized cell adhesion peptides
12/28/2006	US20060293223 Uses of melanocortin-3 receptor (mc3r) agonist peptides
12/28/2006	US20060293222 inhibitor of a phosphodiesterase 4 isoform is selected from cis-4-cyano-4-(3-(cyclopentyloxy)-4-methoxyphenyl) cyclohexane-1-carboxylic acid; 2-(4-(6,7-diethoxy-2,3bis(hydroxymethyl)napthalen-1-yl)pyridin-2-yl)-)-4-(3-pyridyl)pthalazin-1 (2H)-one hydrochloride; roflumilast, piclamilast, arofylline
12/28/2006	US20060293221 Mucosal repair by TFF2 peptides
12/28/2006	US20060293220 Thermodynamically stable calcium phosphate nanoclusters formed from a solution of calcium, phosphate and casein-type peptides; food and beverage additives; used for treatment of pathological calcification and prevention of tooth demineralization
12/28/2006	US20060293219 Methods of treating diabetes mellitus
12/28/2006	US20060293218 Salicylate therapeutic compound and process for controlled delivery thereof
12/28/2006	US20060293217 Pharmaceutical formulations for sustained release
12/28/2006	US20060293216 Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion
12/28/2006	US20060292691 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
12/28/2006	US20060292689 CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
12/28/2006	US20060292683 Cross-beta structures on microbial organisms
12/28/2006	US20060292673 For degradation of glycosaminoglycans; inhibiting angiogenesis and cellular proliferation; treating cancer, neurodegenerative disease, atherosclerosis and microbial infection
12/28/2006	US20060292670 Nell peptide expression systems and bone formation activity of nell peptide
12/28/2006	US20060292668 Nuclear factor of activated t cell receptor
12/28/2006	US20060292655 2-O sulfatase compositions and methods of analyzing therewith
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292631 Elastin peptide fingerprints and analysis methods for mmp12 related to copd
12/28/2006	US20060292629 Chimeric polypeptides and their use
12/28/2006	US20060292625 Novel human leucine-rich repeat domain containing protein HLLRCR-1
12/28/2006	US20060292622 determining the presence of or predisposition to early-onset spinocerebellar ataxia with ocular motor aprataxia and hypoalbuminemia in a human; neurodegenerative disease
12/28/2006	US20060292613 Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
12/28/2006	US20060292606 Using g-protein coupled receptor to identify modulators for prevention and treatment of schizophrenia and related psychoses
12/28/2006	US20060292598 Nucleotide sequences coding mitogenic racemase for use diagnostic probe in detection and prevention of parasite infection; immunotherapy
12/28/2006	US20060292596 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
12/28/2006	US20060292593 Nucleotide sequences coding B7 immune response regulatory protein selectively expressed on dendritic cells for use as therapeutic tool in targeting viral and tumor cell for destruction
12/28/2006	US20060292563 Methods of diagnosing & treating diabetes and insulin resistance
12/28/2006	US20060292551 cationic peptides useful in the treatment of dermatitis and viral infections; for topical administration
12/28/2006	US20060292224 Pharmaceutical composition
12/28/2006	US20060292205 Substitute for animal protein in cattle feed
12/28/2006	US20060292199 PMMA bone cement containing antibiotic/antibiotics
12/28/2006	US20060292186 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
12/28/2006	US20060292180 Contacting the sample with an isolated antibody specific for an EspA polypeptide, wherein the polypeptide is a secreted protein from enteropathogenic E. coli, detecting binding of the antibody to EspA polypeptide
12/28/2006	US20060292177 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
12/28/2006	US20060292169 Fusion proteins of mycobacterium tuberculosis antigens and their uses
12/28/2006	US20060292166 Vaccine composition comprising Flt3-ligand
12/28/2006	US20060292161 Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections
12/28/2006	US20060292158 Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative
12/28/2006	US20060292157 MDA-7 protein variants having antiproliferative activity
12/28/2006	US20060292155 Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
12/28/2006	US20060292150 Methods of using wisp antagonists
12/28/2006	US20060292148 Antihuman TNF-alpha antibody activity lowering inhibitor
12/28/2006	US20060292146 Isolated PTPMT1 protein which mediates insulin production and uses thereof
12/28/2006	US20060292144 Human disintegrin protein
12/28/2006	US20060292143 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
12/28/2006	US20060292142 Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
12/28/2006	US20060292140 Humanized immunoglobulin reactive with alpha4beta7 integrin
12/28/2006	US20060292139 Eukaryotic host cell containing a nucleic acid sequence coding for a bivalent or a multivalent glycosylated compound having two or more single polypeptide chain antigen binding regions linked to a prodrug-activating enzyme; transgenic nonhuman mammal having the sequence
12/28/2006	US20060292137 modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties
12/28/2006	US20060292136 Cytotoxic factors for modulating cell death
12/28/2006	US20060292135 Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
12/28/2006	US20060292134 Composition for enhancing cellular energy
12/28/2006	US20060292130 2-O sulfatase nucleic acid compositions
12/28/2006	US20060292122 Adenoviral vectors for treating diseases
12/28/2006	US20060292120 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
12/28/2006	US20060292118 Hollow nanoparticles of protein and drug using the same
12/28/2006	US20060292116 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
12/28/2006	US20060292115 Methods and compositions for treating and preventing inflammatory conditions
12/28/2006	US20060292114 Neurturin receptor
12/28/2006	US20060292113 Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
12/28/2006	US20060292085 Medicaments
12/28/2006	US20060292075 Labelled glutamine and lysine analogues
12/28/2006	DE10356409B4 Neues Arzneimittel Oxachelin und Derivate New drug Oxachelin and derivatives
12/28/2006	DE102005027478A1 Active substance, useful for treating tumors in renal tissue, comprises a peptide toxin, a substance, homeopathic Tarantula D4 in sodium chloride solution and saturated solution of poison cocktail of spiders of Loxoscele laeta
12/28/2006	CA2809723A1 Treatment of autoimmune disorders with a neurotoxin
12/28/2006	CA2655048A1 Effect of bri proteins on a.beta. production
12/28/2006	CA2648732A1 Supravalent compounds
12/28/2006	CA2633030A1 Intralesional treatment of psoriasis
12/28/2006	CA2618184A1 Stable buffered, pharmaceutical compositions including motilin-like peptides
12/28/2006	CA2616557A1 Stable pharmaceutical compositions including motilin-like peptides
12/28/2006	CA2615226A1 Method and compositions for the treatment of diabetes and related complications
12/28/2006	CA2613480A1 Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same
12/28/2006	CA2613257A1 A novel biological substance nesfatin and its related substances and uses thereof
12/28/2006	CA2613247A1 Prophylactic or therapeutic agent for corneal/conjunctival disease
12/28/2006	CA2613244A1 Vitreous body visualization agent
12/28/2006	CA2612811A1 Amylases for pharmaceutical use
12/28/2006	CA2612806A1 Proteases for pharmaceutical use
12/28/2006	CA2612648A1 Lipases for pharmaceutical use
12/28/2006	CA2612646A1 Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
12/28/2006	CA2612522A1 Lkktet and/or lkktnt peptide compositions and methods
12/28/2006	CA2612494A1 Epitope analogues
12/28/2006	CA2612449A1 Receptor antagonists for treatment of metastatic bone cancer
12/28/2006	CA2612417A1 Anti-gfralpha3 antibodies
12/28/2006	CA2612410A1 Lkktet (seq id no: 1) and/or lkktnt (seq id no: 2) peptide compositions wich are lyophilized or in a form capable of being lyophilized
12/28/2006	CA2612405A1 Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage

1 ... 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 ... 3163